Recent News

A team of MSK researchers solved a decades-old scientific puzzle and revealed that a critical inflammatory signaling pathway doesn’t just summon immune cells to the place where they’re needed — it also protects healthy cells from being damaged by the immune response.

Scientists at MSK have developed a new nanoparticle-based approach to breaking down fibrosis in cancer and other diseases, which could make immunotherapy more effective. Learn about their findings in laboratory models.

MSK researchers have discovered that a type of rogue DNA found in aggressive cancers has a hidden structural weakness — and that blocking a single repair protein can cause it to fall apart, suggesting a new therapeutic opportunity.

This year's GSK Chairman’s Prize was awarded to Zaza Gelashvili for his research on how cells sense injury.

Sixteen exceptional early-career scientists are advancing groundbreaking biomedical research at MSK thanks to the generous support of MSK philanthropists. These postdoctoral researchers, selected for their innovative research proposals and scientific promise, represent the future of oncology discovery. 

New MSK research shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; reveals tumor CD19 levels may predict the success of CAR T cell therapy; and finds a new targeted drug combination shows promise in early trial for small cell lung cancer.

How MSK researchers are using artificial intelligence (AI) to design better "binders" for CAR T cell therapies.

MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.

New MSK research uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; creates the first atomic-level images of a key phosphate transporter that could inform treatment of ovarian cancer and kidney disease; finds Medicare Advantage patients with cancer receive optimal treatment at lower cost; and studies how much tissue surgeons should remove for tumor-related epilepsy.

The final paper from the lab of the late MSK Developmental Biology Chair Kathryn Anderson reveals how a critical signaling molecule called WNT guides cells in the embryo from a state of high flexibility — known as "plasticity" — toward distinct, specialized identities. Completing it was a labor of love for her colleagues.